# US 2021/0198368 A1 · Multispecific molecules targeting cll-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198368 A1
- Document ID: US20210198368A1
- Status: Published application
- Kind: A1
- Application number: 16/070,501
- Filed: 2017-01-20
- Published: 2021-07-01
- Earliest claimed: 2016-01-21
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Michael DALEY; Hilmar EBERSBACH; Julia JASCUR; Qilong WU; Qiumei YANG; Jiquan ZHANG
- Web page: https://patentgrep.com/patent/US20210198368A1

## CPC

- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61P 35/00: Antineoplastic agents
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/30: from tumour cells
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/526: CH3 domain
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to multispecific/multivalent molecules comprising an anti-CLL-1 binding domain.

## Claims

### Claim 1

A multispecific molecule comprising a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain is an anti-CLL-1 binding domain comprising:
(i) (a) a heavy chain complementary determining region 1 (HC CDR1) of SEQ ID NO: 317, (b) a heavy chain complementary determining region 2 (HC CDR2) of SEQ ID NO: 331, (c) a heavy chain complementary determining region 3 (HC CDR3) of SEQ ID NO:345 and (d) a light chain complementary determining region 1 (LC CDR1) of SEQ ID NO: 359, (e) a light chain complementary determining region 2 (LC CDR2) of SEQ ID NO:373, and (f) a light chain complementary determining region 3 (LC CDR3) of SEQ ID NO:387;
(ii) (a) a HC CDR1 of SEQ ID NO:315, (b) a HC CDR2 of SEQ ID NO:329, (c) a HC CDR3 of SEQ ID NO:343 and (d) a LC CDR1 of SEQ ID NO: 357, (e) a LC CDR2 of SEQ ID NO: 371, and (f) a LC CDR3 of SEQ ID NO: 385; or
(iii) (a) a HC CDR1 of SEQ ID NO:321, (b) a HC CDR2 of SEQ ID NO:335, (c) a HC CDR3 of SEQ ID NO:349 and (d) a LC CDR1 of SEQ ID NO:363, (e) a LC CDR2 of SEQ ID NO:377, and (f) a LC CDR3 of SEQ ID NO:391.

### Claim at position 2

-4. (canceled)

### Claim 5 (depends on 1)

The multispecific molecule of claim 1, wherein the anti-CLL-1 binding domain comprises:
(i) an amino acid sequence of light chain variable region of SEQ ID NO:81 and heavy chain variable region of SEQ ID NO:68;
(ii) an amino acid sequence of light chain variable region of SEQ ID NO:79 and heavy chain variable region of SEQ ID NO:66; or
(iii) an amino acid sequence of light chain variable region of SEQ ID NO:85 and heavy chain variable region of SEQ ID NO:72.

### Claim 6 (depends on 5)

The multispecific molecule of claim 5, wherein the anti-CLL-1 binding domain comprises:
an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications of the amino acid sequence of the light chain variable regions or the heavy chain variable regions; or
an amino acid sequence with 95-99% identity to the amino acid sequence of the light chain variable regions or the heavy chain variable regions.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The multispecific molecule of claim 1, wherein the anti-CLL-1 binding domain comprises:
(i) an amino acid sequence of SEQ ID NO: 40, SEQ ID NO: 42, or SEQ ID NO: 46;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20 or 10 modifications to SEQ ID NO: 40, SEQ ID NO: 42, or SEQ ID NO: 46; or
(iii) an amino acid sequence with 95-99% identity to SEQ ID NO: 40, SEQ ID NO: 42, or SEQ ID NO: 46.

### Claim 9 (depends on 1)

The multispecific molecule of claim 1, wherein the second antigen-binding domain binds a cancer antigen other than CLL-1.

### Claim 10 (depends on 9)

The multispecific molecule of claim 9, wherein the cancer antigen other than CLL-1 is expressed on a cell that also expresses CLL-1.

### Claim 11 (depends on 9, 10)

The multispecific molecule of any of claims 9-10, wherein the cancer antigen other than CLL-1 is expressed on an acute myeloid leukemia (AML) cell.

### Claim 12 (depends on 9)

The multispecific molecule of claim 9, wherein the cancer antigen is selected from the group consisting of CD123, CD33, CD34, FLT3, and folate receptor beta.

### Claim 13 (depends on 1)

The multispecific molecule of claim 1, wherein the second antigen-binding domain binds an immune effector cell antigen.

### Claim 14 (depends on 13)

The multispecific molecule of claim 13, wherein the immune effector cell antigen is an antigen expressed on a NK cell.

### Claim 15 (depends on 14)

The multispecific molecule of claim 14, wherein the antigen expressed on a NK cell is CD16 (Fc Receptor gamma III) or CD64 (Fc Receptor gamma I).

### Claim 16 (depends on 13)

The multispecific molecule of claim 13, wherein the immune effector cell antigen is an antigen expressed on a T cell.

### Claim 17 (depends on 16)

The multispecific molecule of claim 16, wherein the antigen expressed on a T cell is an immune costimulatory molecule.

### Claim 18 (depends on 17)

The multispecific molecule of claim 17, wherein the immune costimulatory molecule is selected from the group consisting of an MHC class I molecule, a TNF receptor protein, an immunoglobulin-like protein, a cytokine receptor, an integrin, a signaling lymphocytic activation molecule (SLAM protein), an activating NK cell receptor, BTLA, Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD47, CDS, ICAM-1, LFA-1 (CD11a/CD18), 4-1BB (CD137), B7-H3, CDS, ICAM-1, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), TLR7, LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

### Claim 19 (depends on 16)

The multispecific molecule of claim 16, wherein the antigen expressed on a T cell is an immune inhibitory molecule.

### Claim 20 (depends on 19)

The multispecific molecule of claim 19, wherein the immune inhibitory molecule is selected from the group consisting of PD1, PD-L1, PD-L2, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and/or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MEW class I, MHC class II, GALS, adenosine, and TGFR beta.

### Claim 21 (depends on 16)

The multispecific molecule of claim 16, wherein the antigen expressed on a T cell is CD3.

### Claim at position 20

-29. (canceled)

### Claim 30 (depends on 21)

The multispecific molecule of claim 21, wherein an anti-CD3 binding domain (i.e., the second antigen-binding domain) comprises a heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NO: 1200, 1202, 1204, 1206, 1208, 1210, 1212, 1214, 1216, 1218, 1220, 1222, 1224, 1226, 1228, 1230, 1232, 1234, and 1236; and a light chain variable amino acid sequence selected from the group consisting of SEQ ID NO: 1201, 1203, 1205, 1207, 1209, 1211, 1213, 1215, 1217, 1219, 1221, 1223, 1225, 1227, 1229, 1231, 1233, 1235, and 1237.

### Claim 31 (depends on 21)

The multispecific molecule of claim 21, wherein the second antigen binding domain binds CD3 and comprises a VL sequence of SEQ ID NO: 1209 and a VH sequence of SEQ ID NO: 1236; and wherein the anti-CLL-1 binding domain comprises:
d) a VL sequence of SEQ ID NO: 85 and a VH sequence of SEQ ID NO: 72;
h) a VL sequence of SEQ ID NO: 79 and a VH sequence of SEQ ID NO: 66; or
i) a VL sequence of SEQ ID NO: 81 and a VH sequence of SEQ ID NO: 68.

### Claim 32 (depends on 21)

The multispecific molecule of claim 21, wherein the second antigen binding domain binds CD3 and comprises SEQ ID NO: 506; and wherein the anti-CLL-1 binding domain comprises:
d) SEQ ID NO: 46;
h) SEQ ID NO: 40; or
i) SEQ ID NO: 42.

### Claim 33 (depends on 21)

The multispecific molecule of claim 21, wherein the polypeptide comprising the second antigen binding domain comprises, e.g., consists of, SEQ ID NO: 507; and wherein the polypeptide comprising the anti-CLL-1 binding domain comprises, e.g., consists of:
SEQ ID NO: 527;
SEQ ID NO: 552.

### Claim 34 (depends on 1)

The multispecific molecule of claim 1, wherein said molecule is multivalent, e.g., bivalent, with respect to the first antigen binding domain or second antigen binding domain.

### Claim 35 (depends on 34)

The multispecific molecule of claim 34, wherein the molecule is bivalent with respect to the anti-CLL-1 binding domain.

### Claim 36 (depends on 35)

The multispecific molecule of claim 35, wherein the multispecific molecule is a bispecific antibody.

### Claim 37 (depends on 1)

The multispecific molecule of claim 1, wherein the multispecific molecule is a dualbody.

### Claim 38 (depends on 1)

The multispecific molecule of claim 1, wherein the multispecific molecule is a scFv-Fc.

### Claim 39 (depends on 1)

The multispecific molecule of claim 1, wherein the multispecific molecule is a mixed chain multispecific molecule.

### Claim 40 (depends on 1)

The multispecific molecule of claim 1, wherein the molecule is bispecific.

### Claim 41 (depends on 1)

The multispecific molecule of claim 1, wherein the multispecific molecule is a tandem scFv.

### Claim 42 (depends on 41)

The multispecific molecule of claim 41, wherein the molecule is bispecific.

### Claim 43 (depends on 1)

The multispecific molecule of claim 1, wherein the polypeptides comprising the HC CDR sequences of the first and/or second antigen binding domain further comprise a CH3 domain, and optionally a CH2 domain.

### Claim 44 (depends on 43)

The multispecific molecule of claim 43, wherein at least one, e.g., both, of said CH3 domains comprise one or more modifications to enhance heterodimerization, e.g., as described herein.

### Claim 45 (depends on 44)

The multispecific molecule of claim 44, wherein the one or more modifications to enhance heterodimerization comprises introduction of a knob in a first CH3 domain and a hole in a second CH3 domain, or vice versa, such that heterodimerization of the polypeptide comprising the first CH3 domain and the polypeptide comprising the second CH3 domain is favored relative to polypeptides comprising unmodified CH3 domains.

### Claim 46 (depends on 45)

The multispecific molecule of claim 45, wherein the knob or hole is introduced to the first CH3 domain at residue 366, 405 or 407 according to the EU numbering scheme of Kabat et al. (pp. 688-696 in Sequences of proteins of immunological interest, 5th ed., Vol. 1 (1991; NIH, Bethesda, Md.)) to create either a knob or hole, and a complimentary hole or knob is introduced to the second CH3 domain at residue 407 if residue 366 is mutated in the first CH3 domain, residue 394 if residue 405 is mutated in the first CH3 domain, or residue 366 if residue 407 is mutated in the first CH3 domain, according to the EU numbering scheme of Kabat et al. (pp. 688-696 in Sequences of proteins of immunological interest, 5th ed., Vol. 1 (1991; NIH, Bethesda, Md.)).

### Claim 47 (depends on 44, 45)

The multispecific molecule of any of claims 44-45, wherein the first CH3 domain comprises introduction of a knob at position 366, and the second CH3 domain comprises introduction of a hole at position 366, position 368 and position 407, according to the EU numbering scheme of Kabat et al. (pp. 688-696 in Sequences of proteins of immunological interest, 5th ed., Vol. 1 (1991; NIH, Bethesda, Md.)), or vice versa.

### Claim 48 (depends on 47)

The multispecific molecule of claim 47, wherein the first CH3 domain comprises a tyrosine or tryptophan at position 366, and the second CH3 domain comprises a serine at position 366, alanine at position 368 and valine at position 407, according to the EU numbering scheme of Kabat et al. (pp. 688-696 in Sequences of proteins of immunological interest, 5th ed., Vol. 1 (1991; NIH, Bethesda, Md.)), or vice versa.

### Claim 49 (depends on 44)

The multispecific molecule of claim 44, wherein the one or more modifications comprise IgG heterodimerization modifications.

### Claim 50 (depends on 49)

The multispecific molecule of claim 49, wherein the first CH3 domain comprises the mutation K409R and the second CH3 domain comprises the mutation F405L, or vice versa.

### Claim 51 (depends on 44)

The multispecific molecule of claim 44, wherein the one or more modifications comprise polar bridge modifications.

### Claim 52 (depends on 51)

The multispecific molecule of claim 51, wherein said one or more modifications to the first CH3 domain are selected from a group consisting of: S364L, T366V, L368Q, D399K, F4055, K409F, T411K, and combinations thereof.

### Claim 53 (depends on 52)

The multispecific molecule of claim 52, comprising one more modifications to the second CH3 domain, wherein said one or more modifications are selected from the group consisting of Y407F, K409Q and T411D, and combinations thereof.

### Claim 54 (depends on 43)

The multispecific molecule of claim 43, wherein the first CH3 domain comprises a cysteine capable for forming a disulfide bond with a cysteine of the second CH3 domain.

### Claim 55 (depends on 54)

The multispecific molecule of claim 54, wherein the first CH3 domain comprises a cysteine at position 354 and the second CH3 domain comprises a cysteine at position 349, or vice versa.

### Claim 56 (depends on 43)

The multispecific molecule of claim 43, wherein the multispecific molecule comprises an Fc domain, and wherein the Fc domain comprises one or more mutations, e.g., one mutation, that reduces, e.g., silences, an effector function, e.g., an ADCC and/or CDC function.

### Claim 57 (depends on 56)

The multispecific molecule of claim 56, wherein the one or more mutations comprise a LALA mutation, a DAPA mutation, or combination thereof.

### Claim 58 (depends on 1)

An isolated nucleic acid, e.g., one or more polynucleotides, encoding the multispecific molecule of claim 1.

### Claim 59 (depends on 58)

The isolated nucleic acid of claim 58, disposed on a single continuous polynucleotide.

### Claim 60 (depends on 58)

The isolated nucleic acid of claim 58, disposed on two or more continuous polynucleotides.

### Claim 61 (depends on 58, 59, 60)

The isolated nucleic acid of any of claims 58-60, comprising SEQ ID NO: 508 and SEQ ID NO: 509.

### Claim 62 (depends on 61)

The isolated nucleic acid of claim 61, comprising SEQ ID NO: 510.

### Claim 63 (depends on 61, 62)

The isolated nucleic acid of claim 61 or 62, comprising SEQ ID NO: 511.

### Claim 64 (depends on 58)

The isolated nucleic acid of claim 58, further comprising:
SEQ ID NO: 528 and SEQ ID NO: 529;
SEQ ID NO: 553 and SEQ ID NO: 554.

### Claim 65 (depends on 58)

The isolated nucleic acid of claim 58, comprising:
SEQ ID NO: 530;
SEQ ID NO: 555.

### Claim 66 (depends on 58, 59, 60, 61, 62, 63, 64, 65)

The isolated nucleic acid of claim 58-65, comprising:
SEQ ID NO: 556.

### Claim 67 (depends on 58, 59, 60, 61, 62, 63, 64, 65, 66)

A vector e.g., one or more vectors, comprising the isolated nucleic acid of any of claims 58-66.

### Claim 68 (depends on 67)

A cell comprising the vector of claim 67.

### Claim 69 (depends on 1)

A method of treating a mammal having a disease associated with expression of CLL-1 comprising administering to the mammal an effective amount of a multispecific molecule of any of claim 1.

### Claim 70 (depends on 69)

The method of claim 69, wherein the disease associated with CLL-1 expression is:
(i) a cancer or malignancy, or a precancerous condition chosen from one or more of a myelodysplasia, a myelodysplastic syndrome or a preleukemia, or
(ii) a non-cancer related indication associated with expression of CLL-1.

### Claim 71 (depends on 69, 70)

The method of claim 69 or 70, wherein the disease is a hematologic cancer.

### Claim 72 (depends on 71)

The method of claim 71, wherein the disease is an acute leukemia chosen from one or more of acute myeloid leukemia (AML); acute lymphoblastic B-cell leukemia (B-cell acute lymphoid leukemia, BALL), acute lymphoblastic T-cell leukemia (T-cell acute lymphoid leukemia (TALL), B-cell prolymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia (CML), myelodysplastic syndrome, plasma cell myeloma, or a combination thereof.

### Claim 73 (depends on 72)

The method of claim 72, wherein the disease is acute myeloid leukemia (AML).

### Claim at position 65

-81. (canceled)
